As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company (NYSE:BDX) are reporting robust financial performances that highlight their resilience and strategic adaptability. The company’s stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.The medical device giant reported adjusted earnings per share of $3.68, up from $3.50 a year ago, beating the consensus of $3.41.The company reported third-quarter 2025 sales of $5.51 billion, beating the consensus of $5.49 billion.Also Read: Becton’s Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion MergerRevenues increased 10.4% as reported, 8.5% adjusted FXN, and 3.0% organic.GAAP and adjusted gross margin up 160 basis points and 50 basis points, respectively, and GAAP and adjusted operating income up 46.6% and 11.3%, respectively.Medical segmentBD Medical segment sales increased 14.4% (+3.2% organically) $2.93 billion.Medication Delivery Solutions saw higher volumes, mainly due to gaining ...Full story available on Benzinga.com
Becton Dickinson Q3 Beats Estimates On Medical Device Boom
